SIG
CHRS icon

Sargent Investment Group’s Coherus Oncology CHRS Stock Holding History

Sargent Investment Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,670
Closed -$13.5K – 237
2025
Q1 		$13.5K Sell
16,670
-7,615
-31% -$8.76K ﹤0.01% 232
2024
Q4 		$35.7K Sell
24,285
-18,845
-44% -$21.1K 0.01% 233
2024
Q3 		$44.9K Hold
43,130
– – 0.01% 210
2024
Q2 		$74.6K Sell
43,130
-5,570
-11% -$11.2K 0.02% 212
2024
Q1 		$116K Buy
48,700
+22,640
+87% +$55.7K 0.03% 192
2023
Q4 		$86.8K Buy
26,060
+6,368
+32% +$17.1K 0.02% 204
2023
Q3 		$73.6K Hold
19,692
– – 0.02% 197
2023
Q2 		$84.1K Buy
+19,692
New +$116K 0.02% 192
2023
Q1 		– Sell
-11,200
Closed -$88.7K – 199
2022
Q4 		$88.7K Sell
11,200
-3,970
-26% -$30.5K 0.03% 186
2022
Q3 		$148K Sell
15,170
-6,355
-30% -$64.3K 0.05% 173
2022
Q2 		$156K Sell
21,525
-5,105
-19% -$44.4K 0.05% 171
2022
Q1 		$344K Sell
26,630
-13,104
-33% -$167K 0.09% 137
2021
Q4 		$634K Sell
39,734
-6,806
-15% -$119K 0.14% 107
2021
Q3 		$748K Sell
46,540
-51,195
-52% -$750K 0.18% 95
2021
Q2 		$1.35M Sell
97,735
-6,748
-6% -$95.6K 0.32% 56
2021
Q1 		$1.53M Buy
104,483
+6,739
+7% +$114K 0.4% 49
2020
Q4 		$1.7M Sell
97,744
-8,092
-8% -$144K 0.54% 39
2020
Q3 		$1.94M Buy
105,836
+14,656
+16% +$273K 0.71% 31
2020
Q2 		$1.66M Buy
91,180
+9,505
+12% +$161K 0.63% 35
2020
Q1 		$1.32M Buy
81,675
+17,420
+27% +$322K 0.61% 38
2019
Q4 		$1.16M Buy
64,255
+22,720
+55% +$419K 0.42% 49
2019
Q3 		$841K Buy
41,535
+24,920
+150% +$498K 0.38% 64
2019
Q2 		$367K Buy
+16,615
New +$289K 0.17% 99

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Sargent Investment Group's CHRS Position: Q2 2025 in Review

Sargent Investment Group sold out of Coherus Oncology (CHRS) in Q2 2025, closing a stake of 16,670 shares — an estimated $13.5K sold.

Sargent Investment Group first reported a position in CHRS in Q2 2019 and held it in 23 quarters. The position peaked at $1.94M in Q3 2020. 112 funds tracked by Wall St. Rank hold CHRS as of Q2 2025.

  • Sargent Investment Group reported no remaining Coherus Oncology position as of Q2 2025 after selling out during the quarter.
  • Sargent Investment Group sold 16,670 Coherus Oncology shares in Q2 2025, an estimated $13.5K.
  • Sargent Investment Group first reported a position in Coherus Oncology in Q2 2019 and held it in 23 quarters.
  • Sargent Investment Group's Coherus Oncology position peaked at $1.94M in Q3 2020.
  • 112 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2025.

Based on Sargent Investment Group's 13F filing for Q2 2025, filed 14 Aug 2025.